Bone Metastasis Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | BiologicsMD, Shanghai JMT-Bio Inc., AlaMab Therapeutics, Exelixis

September 05 10:08 2023
Bone Metastasis Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | BiologicsMD, Shanghai JMT-Bio Inc., AlaMab Therapeutics, Exelixis
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Bone Metastasis pipeline constitutes 10+ key companies continuously working towards developing 10+ Bone Metastasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Bone Metastasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Bone Metastasis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bone Metastasis Market.


Some of the key takeaways from the Bone Metastasis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Bone Metastasis treatment therapies with a considerable amount of success over the years. 
  • Bone Metastasis companies working in the treatment market are BiologicsMD, Shanghai JMT-Bio Inc., AlaMab Therapeutics, Exelixis, Mabwell (Shanghai) Bioscience Co., Ltd, Qilu Pharmaceutical Co., Ltd., and others, are developing therapies for the Bone Metastasis treatment 
  • Emerging Bone Metastasis therapies in the different phases of clinical trials are- BMD 3151, JMT103, ALMB-0168, Cabozantinib, MW032, QL1206, and others are expected to have a significant impact on the Bone Metastasis market in the coming years.   
  • In March 2020, A multi-center, randomised, double-blind, parallel-controlled Phase III clinical study to assess the effectiveness and safety of recombinant human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva®) in patients with bone metastases from solid tumours was started by Mabwell (Shanghai) Bioscience Co., Ltd.
  • In October 2022, A phase II clinical trial suggests that treating high-risk, asymptomatic bone metastases with radiation may lessen uncomfortable side effects and hospitalisations as well as potentially extend overall survival in people whose cancer has spread to various locations.


Bone Metastasis Overview

When cancer cells from other parts of the body travel to the bone, this is known as bone metastasis. The spine is where bone metastases occurs most frequently. Bone pain is one of the first signs that someone may experience.


Get a Free Sample PDF Report to know more about Bone Metastasis Pipeline Therapeutic Assessment-


Emerging Bone Metastasis Drugs Under Different Phases of Clinical Development Include:

  • BMD 3151: BiologicsMD
  • JMT103: Shanghai JMT-Bio Inc.
  • ALMB-0168: AlaMab Therapeutics
  • Cabozantinib: Exelixis
  • MW032: Mabwell (Shanghai) Bioscience Co., Ltd.
  • QL1206: Qilu Pharmaceutical Co., Ltd.


Bone Metastasis Route of Administration

Bone Metastasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous


Bone Metastasis Molecule Type

Bone Metastasis Products have been categorized under various Molecule types, such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine


Bone Metastasis Pipeline Therapeutics Assessment

  • Bone Metastasis Assessment by Product Type
  • Bone Metastasis By Stage and Product Type
  • Bone Metastasis Assessment by Route of Administration
  • Bone Metastasis By Stage and Route of Administration
  • Bone Metastasis Assessment by Molecule Type
  • Bone Metastasis by Stage and Molecule Type


DelveInsight’s Bone Metastasis Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Further Bone Metastasis product details are provided in the report. Download the Bone Metastasis pipeline report to learn more about the emerging Bone Metastasis therapies


Some of the key companies in the Bone Metastasis Therapeutics Market include:

Key companies developing therapies for Bone Metastasis are – Medtronic, General Electric Company, FUJIFILM Corporation, Koninklijke Philips N.V, Canon Medical Systems, Siemens Healthcare GmbH, Carestream Health, USA, Hitachi, Ltd, Brainlab AG and FMI Medical Systems, Inc., and others


Bone Metastasis Pipeline Analysis:

The Bone Metastasis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Bone Metastasis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bone Metastasis Treatment.
  • Bone Metastasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Bone Metastasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bone Metastasis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Bone Metastasis drugs and therapies


Bone Metastasis Pipeline Market Drivers

  • Rise in the number of cases of cancers worldwide, development of promising circulating and tissue biomarkers are some of the important factors that are fueling the Bone Metastasis Market.


Bone Metastasis Pipeline Market Barriers

  • However, lack of healthcare services in low-income countries, lack of an effective multidisciplinary approach for treatment and other factors are creating obstacles in the Bone Metastasis Market growth.


Scope of Bone Metastasis Pipeline Drug Insight    

  • Coverage: Global
  • Key Bone Metastasis Companies: BiologicsMD, Shanghai JMT-Bio Inc., AlaMab Therapeutics, Exelixis, Mabwell (Shanghai) Bioscience Co., Ltd, Qilu Pharmaceutical Co., Ltd., and others
  • Key Bone Metastasis Therapies: BMD 3151, JMT103, ALMB-0168, Cabozantinib, MW032, QL1206, and others
  • Bone Metastasis Therapeutic Assessment: Bone Metastasis current marketed and Bone Metastasis emerging therapies
  • Bone Metastasis Market Dynamics: Bone Metastasis market drivers and Bone Metastasis market barriers 


Request for Sample PDF Report for Bone Metastasis Pipeline Assessment and clinical trials


Table of Contents 

1. Bone Metastasis Report Introduction

2. Bone Metastasis Executive Summary

3. Bone Metastasis Overview

4. Bone Metastasis- Analytical Perspective In-depth Commercial Assessment

5. Bone Metastasis Pipeline Therapeutics

6. Bone Metastasis Late Stage Products (Phase II/III)

7. Bone Metastasis Mid Stage Products (Phase II)

8. Bone Metastasis Early Stage Products (Phase I)

9. Bone Metastasis Preclinical Stage Products

10. Bone Metastasis Therapeutics Assessment

11. Bone Metastasis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Bone Metastasis Key Companies

14. Bone Metastasis Key Products

15. Bone Metastasis Unmet Needs

16 . Bone Metastasis Market Drivers and Barriers

17. Bone Metastasis Future Perspectives and Conclusion

18. Bone Metastasis Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States